Literature DB >> 8613909

Carvedilol, a new beta adrenoreceptor blocker and free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits.

X L Ma1, T L Yue, B L Lopez, F C Barone, T A Christopher, R R Ruffolo, G Z Feuerstein.   

Abstract

Oxygen-derived free radicals play a critical role in atherogenesis and reperfusion injury. The present experiment evaluated the effects of carvedilol, a new beta adrenoreceptor blocker with potent free radical-scavenging activity, on myocardial ischemia and reperfusion injury in a hypercholesterolemic rabbit model. New Zealand rabbits were fed a normal diet, a high-cholesterol diet, or a high-cholesterol diet supplemented with 1200 ppm carvedilol or propranolol. Eight weeks later, the rabbits were subjected to 60 min of myocardial ischemia followed by 60 min of reperfusion. The nontreated cholesterol-fed animals experienced greater cardiac damage after ischemia and reperfusion than rabbits fed a normal diet (necrosis 51% +/- 4% vs. 28% +/- 3% in the normal-diet group, P < .01). In addition, nontreated cholesterol-fed rabbits showed a significantly decreased vasorelaxant response to ACh in U-46619-precontracted aortic rings (56% +/- 5% vs 90% +/- 3% in the control group, P < .001). Treatment with propranolol neither preserved endothelial function after cholesterol feeding nor reduced neutrophil accumulation in ischemic-reperfused myocardial tissue. Propranolol treatment did significantly decrease HR, pressure-rate index and infarct size (necrosis 33% +/- 4%). Despite their having essentially identical effects on HR and pressure-rate index, carvedilol exerted more profound cardiac protective effects than propranolol (necrosis 19% +/- 3%). Moreover, carvedilol treatment significantly preserved aortic endothelial function and markedly reduced neutrophil accumulation in ischemic-reperfused myocardial tissue. These results indicate that in addition to its beta blocking activity, the antioxidant and endothelial protective activities of carvedilol contributed significantly to its cardiac protective effects after ischemia and reperfusion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8613909

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

Review 1.  Myocardial ischaemia/reperfusion injury and preconditioning: effects of hypercholesterolaemia/hyperlipidaemia.

Authors:  Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

Review 2.  Sarcolemmal dependence of cardiac protection and stress-resistance: roles in aged or diseased hearts.

Authors:  Louise E See Hoe; Lauren T May; John P Headrick; Jason N Peart
Journal:  Br J Pharmacol       Date:  2016-09-09       Impact factor: 8.739

3.  Increased superoxide anion production is associated with early atherosclerosis and cardiovascular dysfunctions in a rabbit model.

Authors:  Bertrand Collin; David Busseuil; Marianne Zeller; Caroline Perrin; Olivier Barthez; Laurence Duvillard; Catherine Vergely; Marc Bardou; Monique Dumas; Yves Cottin; Luc Rochette
Journal:  Mol Cell Biochem       Date:  2006-07-27       Impact factor: 3.396

Review 4.  Effect of hypercholesterolaemia on myocardial function, ischaemia-reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning.

Authors:  Ioanna Andreadou; Efstathios K Iliodromitis; Antigone Lazou; Anikó Görbe; Zoltán Giricz; Rainer Schulz; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2017-02-08       Impact factor: 8.739

5.  Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms.

Authors:  Pattipati S Naidu; Amanpreet Singh; Shrinivas K Kulkarni
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

6.  Effect of carvedilol on behavioral, mitochondrial dysfunction, and oxidative damage against D-galactose induced senescence in mice.

Authors:  Anil Kumar; Samrita Dogra; Atish Prakash
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-08-15       Impact factor: 3.000

7.  Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension.

Authors:  Jennifer I Drake; Jose Gomez-Arroyo; Catherine I Dumur; Donatas Kraskauskas; Ramesh Natarajan; Harm J Bogaard; Paul Fawcett; Norbert F Voelkel
Journal:  Physiol Genomics       Date:  2013-04-30       Impact factor: 3.107

Review 8.  Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again.

Authors:  Kurt W Prins; Thenappan Thenappan; E Kenneth Weir; Rajat Kalra; Marc Pritzker; Stephen L Archer
Journal:  J Am Heart Assoc       Date:  2019-01-08       Impact factor: 5.501

9.  Identification of gene signatures regulated by carvedilol in mouse heart.

Authors:  Jian-Peng Teoh; Kyoung-Mi Park; Zuzana Broskova; Felix R Jimenez; Ahmed S Bayoumi; Krystal Archer; Huabo Su; John Johnson; Neal L Weintraub; Yaoliang Tang; Il-Man Kim
Journal:  Physiol Genomics       Date:  2015-07-07       Impact factor: 3.107

10.  Carvedilol-responsive microRNAs, miR-199a-3p and -214 protect cardiomyocytes from simulated ischemia-reperfusion injury.

Authors:  Kyoung-Mi Park; Jian-Peng Teoh; Yongchao Wang; Zuzana Broskova; Ahmed S Bayoumi; Yaoliang Tang; Huabo Su; Neal L Weintraub; Il-Man Kim
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-06-10       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.